118 related articles for article (PubMed ID: 36680930)
1. Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
Pérez-Montiel D; Olivares-Mundo A; Jiménez-Ríos MA; Morera CS; Scavuzzo A; Orozco-Mora A; Prada D; Cantú-de León D
Ann Diagn Pathol; 2023 Apr; 63():152081. PubMed ID: 36680930
[TBL] [Abstract][Full Text] [Related]
2. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
3. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder.
Rodriguez Pena MDC; Chaux A; Eich ML; Tregnago AC; Taheri D; Borhan W; Sharma R; Rezaei MK; Netto GJ
Virchows Arch; 2019 Sep; 475(3):349-356. PubMed ID: 31300876
[TBL] [Abstract][Full Text] [Related]
5. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
6. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
7. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
8. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
Kim JM; Choi E; Sung SH; Kang H; Park S
Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
[TBL] [Abstract][Full Text] [Related]
9. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
[TBL] [Abstract][Full Text] [Related]
10. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
12. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
Barth I; Schneider U; Grimm T; Karl A; Horst D; Gaisa NT; Knüchel R; Garczyk S
Virchows Arch; 2018 May; 472(5):749-758. PubMed ID: 29654370
[TBL] [Abstract][Full Text] [Related]
13. In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival.
Breyer J; Wirtz RM; Otto W; Erben P; Kriegmair MC; Stoehr R; Eckstein M; Eidt S; Denzinger S; Burger M; Hartmann A;
Virchows Arch; 2017 Mar; 470(3):267-274. PubMed ID: 28074276
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
15. Greater utility of molecular subtype rather than epithelial-to-mesenchymal transition (EMT) markers for prognosis in high-risk non-muscle-invasive (HGT1) bladder cancer.
Ottley EC; Pell R; Brazier B; Hollidge J; Kartsonaki C; Browning L; O'Neill E; Kiltie AE
J Pathol Clin Res; 2020 Oct; 6(4):238-251. PubMed ID: 32374509
[TBL] [Abstract][Full Text] [Related]
16. Analysis of bladder cancer subtypes in neurogenic bladder tumors.
Manach Q; Cussenot O; Rouprêt M; Gamé X; Chartier-Kastler E; Reus C; Camparo P; Compérat E; Phé V
Can J Urol; 2018 Feb; 25(1):9161-9167. PubMed ID: 29524970
[TBL] [Abstract][Full Text] [Related]
17. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
[TBL] [Abstract][Full Text] [Related]
18. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
19. Basal-subtype bladder tumours show a 'hot' immunophenotype.
Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
Histopathology; 2018 Nov; 73(5):748-757. PubMed ID: 29947424
[TBL] [Abstract][Full Text] [Related]
20. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]